Snap-8 is a topical cosmetic peptide. It appears on ingredient lists as acetyl octapeptide-3, and it is sold as a longer version of the more familiar Argireline. If you are trying to work out what it is and whether the research supports the claims made for it, the short answer is that the chemistry is well defined and the clinical literature is almost non-existent. Two papers on PubMed mention it, and in both it is one ingredient among several.
This page sets out what is established, what is proposed, and what has not been tested.
What Snap-8 actually is
Snap-8 is a trade name. The compound behind it is catalogued as follows.
| Property | Value |
|---|---|
| INCI name | Acetyl octapeptide-3 |
| Also listed as | Acetyl glutamyl heptapeptide-3, acetyl octapeptide-1 |
| CAS number | 868844-74-0 |
| Sequence | Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH2 |
| Molecular formula | C41H70N16O16S |
| Molecular weight | 1,075.2 g/mol |
| PubChem CID | 76283482 |
It is an eight amino acid chain with an acetyl group on the N-terminus and an amide on the C-terminus. Both modifications are standard ways of making a short peptide more stable in a formulation.
Snap-8 and Argireline are not the same molecule
Argireline is the trade name for acetyl hexapeptide-8, a six amino acid peptide. Snap-8 is eight amino acids. The first six residues are the same and Snap-8 adds two more.
Suppliers often describe Snap-8 as an improved or extended Argireline. That description is accurate as chemistry. It is not, on the published evidence, a statement about performance, because no trial has compared the two directly in the same protocol.
The proposed mechanism
Both peptides are modelled on a fragment of SNAP-25, a protein involved in the SNARE complex that allows nerve cells to release their signalling vesicles. The idea is that a peptide resembling part of SNAP-25 competes with the real protein, so slightly less neurotransmitter is released and the small facial muscles that produce expression lines contract less strongly.
The clearest description of this in the peer-reviewed literature comes from a trial of the shorter peptide. Lungu and colleagues, writing in the European Journal of Neurology in 2013, characterise acetyl hexapeptide-8 as “a competitive SNAP25 inhibitor” in a double-blind, placebo-controlled study of 24 patients. That study was conducted in a clinical population under specialist care and is not a cosmetic result. It is cited here only because it is the clearest published statement of the mechanism class.
Two things follow. The mechanism is a reasonable hypothesis with a named molecular target. And it has been characterised for the six amino acid peptide, not for Snap-8.
What the published research on Snap-8 shows
A search of PubMed for “acetyl octapeptide-3” returns two results. Both are studies of microneedle patches, and in both the peptide is one active among several.
Avcil and colleagues, 2020, Journal of Cosmetic Dermatology. A 12 week single-centre trial of hyaluronic acid microneedle patches. The formulation contained an arginine and lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts. The authors reported a 25.8% decrease in fine lines and wrinkles, 15.4% improvement in hydration, and increases of 14.2% and 12.9% in dermal density and thickness. No participant reported a skin reaction.
Shin and colleagues, 2024, Annals of Dermatology. A dissolving microneedle patch combining hyaluronic acid, acetyl octapeptide-3 and L-ascorbic acid 2-glucoside, assessed for safety and wrinkle effects.
Read those carefully. Five actives were applied together in the first study and three in the second. Neither design can tell you what acetyl octapeptide-3 did on its own, and neither set out to. The delivery method was also a microneedle patch rather than a cream, which is a different route into the skin.
What is not established
- No isolated trial. There is no published study of Snap-8 alone against a placebo.
- No head-to-head with Argireline. The claim that eight amino acids outperform six is a formulation argument, not a measured one.
- No established concentration. Supplier literature commonly quotes use at around 10% of a formulation. That figure comes from manufacturers rather than from published trials.
- Nothing on the cream route. Both studies used microneedles. A topical serum has to cross an intact stratum corneum, and a 1,075 g/mol peptide is large for that.
None of this means the ingredient does nothing. It means the evidence base is two multi-ingredient patch studies, and any confident percentage attached to Snap-8 by itself is not coming from the literature.
How to read a Snap-8 listing
Because the compound is well characterised, the specification is checkable even where the efficacy data is thin. A supplier should be able to show you the CAS number 868844-74-0, a stated purity with the method used to measure it, and a batch-specific certificate of analysis rather than a generic one. Our guide to reading a peptide certificate of analysis covers what a real one contains and the checks that catch a fabricated document.
Cosmetic peptide ingredients are usually supplied as a solution rather than a lyophilised powder, which is the opposite of most research peptides. If you are used to the powdered format, the difference is explained in what a lyophilised peptide is. Manufacturing standards and what separates a documented supplier from an undocumented one are covered in our review of GMP-compliant peptide companies.
The short version
Snap-8 is acetyl octapeptide-3, a well defined eight amino acid cosmetic peptide with a plausible and named mechanism borrowed from a better studied relative. The published clinical record consists of two microneedle patch studies in which it was never tested alone. That is a thin evidence base, and it is worth knowing before you read a product page that describes it with a single confident number.
References
- PubChem. Acetyl octapeptide-3, Compound CID 76283482. National Center for Biotechnology Information. pubchem.ncbi.nlm.nih.gov/compound/76283482
- Avcil M, et al. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. Journal of Cosmetic Dermatology. 2020 Feb. PMID 31134751. pubmed.ncbi.nlm.nih.gov/31134751
- Shin JY, et al. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Annals of Dermatology. 2024. PMID 39082657. pubmed.ncbi.nlm.nih.gov/39082657
- Lungu C, et al. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. European Journal of Neurology. 2013 Mar. PMID 23146065. pubmed.ncbi.nlm.nih.gov/23146065
